New drug combo aims to shrink tough head and neck tumors
NCT ID NCT05249426
First seen Jan 29, 2026 · Last updated Jun 18, 2026 · Updated 23 times
Summary
This study tests a mix of antibodies that help the immune system fight cancer, block tumor growth signals, and cut off the tumor's blood supply. It is for adults with head and neck cancer that did not respond to prior treatment or has no standard options. Participants receive infusions every 1 to 3 weeks and are monitored for side effects and tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
"Prof. Dr. Alexandru Trestioreanu" Oncology Institut
Bucharest, 022328, Romania
-
ARENSIA Exploratory Medicine
Chisinau, MD-2025, Moldova
-
ARKE SMO S.A. de C.V
Mexico City, 06700, Mexico
-
CTR Georges-François Leclerc
Dijon, 21079, France
-
CTR Leon Berard
Lyon, 69373, France
-
FAICIC S de RL de C.V.
Veracruz, 91900, Mexico
-
HOP Civil
Strasbourg, 67091, France
-
HOP Timone
Marseille, 13385, France
-
Hammersmith Hospital
London, W12 0HS, United Kingdom
-
Hospital Clínico San Carlos
Madrid, 28040, Spain
-
Hospital Duran i Reynals
L'Hospitalet de Llobregat, 08907, Spain
-
Hospital Sultan Ismail
Johor Bahru, 81100, Malaysia
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
INS Claudius Regaud IUCT-Oncopole
Toulouse, 31059, France
-
INS Curie
Paris, 75248, France
-
Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca
Cluj-Napoca, 400015, Romania
-
Investigacion Biomedica para el Desarrollo de Farmacos, S.A. de C.V.
Zapopan, 45070, Mexico
-
Japanese Foundation for Cancer Research
Tokyo, Koto-ku, 135-8550, Japan
-
King Chulalongkorn Memorial Hospital
Bangkok, 10330, Thailand
-
King's College Hospital
London, SE5 9RS, United Kingdom
-
Mandziuk Slawomir Specialist Medical Practice
Lublin, 20-093, Poland
-
Sarawak General Hospital
Kuching, Sarawak, 93586, Malaysia
-
Songklanagarind Hospital
Songkhla, 90110, Thailand
-
The Royal Marsden Hospital, Chelsea
London, SW3 6JJ, United Kingdom
-
Valkyrie Clinical Trials
Los Angeles, California, 90067, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.